GlassScriptPhysician profile
Micah Lynn Olson
NPI 1417981440
$9,421.67
in general payments reported to CMS, 2019-2025
30 companies · $18.46 in 2025
The $18.46 reported for 2025 was less than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $218 · 2021: $313 · 2022: $5,421 · 2023: $3,050 · 2024: $86.18 · 2025: $18.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,680 · Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,680.00 |
| Food and Beverage | $474.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhythm Pharmaceuticals, INC. | $8,008.35 | 2021-2023 | Imcivree |
| Pfizer INC. | $283.72 | 2019-2023 | |
| Novo Nordisk INC | $167.12 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $120.59 | 2020-2021 | |
| Insulet Corporation | $90.73 | 2020-2023 | Omnipod |
| Medtronic, INC. | $84.82 | 2021-2022 | |
| Abbvie INC. | $63.18 | 2021-2024 | |
| Tolmar Pharmaceuticals, INC. | $60.05 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $59.31 | 2021-2022 | |
| Medtronic Minimed, INC. | $55.50 | 2019-2020 | |
| Abbott Laboratories | $48.23 | 2022-2024 | Freestyle Libre 3 |
| Intuity Medical INC | $45.22 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Lilly USA, LLC | $43.09 | 2020-2023 | Baqsimi |
| Dexcom, INC. | $40.42 | 2023-2024 | Dexcom G6 Transmitter |
| Ipsen Biopharmaceuticals, INC | $36.52 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $27.23 | 2023 | |
| Ferring Pharmaceuticals INC. | $25.38 | 2019 | |
| Lifescan, INC. | $22.97 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.50 | 2024 | |
| Zealand Pharma US, INC. | $18.61 | 2021 | |
| Verity Pharmaceuticals INC. | $18.46 | 2025 | Tlando |
| Xeris Pharmaceuticals, INC. | $17.94 | 2020 | |
| Biomarin Pharmaceutical INC. | $17.75 | 2021 | |
| Tandem Diabetes Care, INC. | $16.53 | 2019 | |
| Companion Medical, INC. | $14.66 | 2020 | |
| Endo Pharmaceuticals INC. | $13.79 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Micah Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.